These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
    Author: Bain J, Rachlis V, Robert E, Khait Z.
    Journal: Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093.
    Abstract:
    A male contraceptive trial was undertaken in 23 men using a combination of oral medroxyprogesterone acetate (MPA) and oral methyltestosterone (MeT). The men were divided into four groups according to varying drug dosages and were followed for 15 months (control - 3 months, treatment - 6 months, follow-up - 6 months). The parameters assessed included sperm count and motility, serum gonadotropins and sex steroids, and several biochemical and hematological tests. A questionnaire dealing with side-effects and changes in sexual function was administered intermittently. Although sperm count was suppressed (most dramatically at the highest drug doses, MPA 20mg,MeT 20mg), it was not suppressed to infertile levels. Sperm motility was unaltered; LH was modestly suppressed, FSH was not suppressed; testosterone was suppressed even at low doses; dihydrotestosterone responses were inconsistent. No significant biochemical abnormalities or side-effects occurred although some men experienced mild transient acne, gynecomastia and decreased testicular size. We conclude that in the doses used in this trial, the combination of MPA and MeT is not effective for male contraceptive, purposes and that higher doses may induce severe and undesirable side-effects. A male contraceptive trial was undertaken with 23 men using a combination of (MPA) oral medroxyprogesterone acetate and (MeT) oral methyltestosterone. The men were divided into 4 groups according to varying drug dosages and were followed for 15 months (control - 3 months; treatment - 6 months; follow-up - 6 months). The parameters assessed included sperm count and motility, serum gonadotropins and sex steroids, as well as several biochemical and hematological tests. A questionnaire dealing with side effects and changes in sexual function was administered intermittently. Although sperm count was suppressed (most dramatically at the highest drug doses, MPA 20 mg, MeT 20 mg), it was suppressed to infertile levels. Sperm motility was unaltered; luteinizing hormone was modestly suppressed; follicle stimulating hormone was not suppressed testosterone was suppressed even at low doses; and dihydrotestosterone responses were inconsistent. No significant biochemical abnormalities or side effects occurred although some men did experience mild transient acne, gynecolmastia, and decreased testicular size. It is concluded that in the doses used in this trial, the combination of MPA and MeT is not effective for male contraceptive purposes and that higher doses may induce severe and undesirable side effects.
    [Abstract] [Full Text] [Related] [New Search]